#United States #Chicago #cancer therapies #Hanx Biopharmaceuticals #Bispecific Antibodies

Hanx Biopharmaceuticals: Pioneering the Future of Cancer Treatment

At the 2025 American Association for Cancer Research (AACR) Annual Meeting held in Chicago, Hanx Biopharmaceuticals Ltd. (HanxBio) demonstrated its innovative approach to treating cancer, showcasing five groundbreaking therapies that are set to redefine standard practices in oncology. The presentations included a series of research posters focusing on advanced immunotherapies, specifically emphasizing bispecific antibodies and a novel CSF-1R inhibitor.

Key Highlights from the AACR Presentations

1. HX044: This first-in-class (FIC) CTLA-4xSIRPα bispecific antibody fusion protein is being touted as a major advancement in combating PD-1-resistant solid tumors such as non-small cell lung cancer, melanoma, and renal cell carcinoma. Currently undergoing Phase I trials, HX044 aims to enhance safety while amplifying anti-tumor immunity, marking it as a significant stride in overcoming the limitations of existing immunotherapies.

2. HX035: Designed for addressing inflammatory and autoimmune diseases, this preclinical bispecific antibody targets OX40 with a unique mechanism that binds two distinct OX40 epitopes. By honing in on precision modulation of immune responses, HX035 is on track to become a best-in-class (BIC) therapeutic option for patients facing severe autoimmune challenges.

3. HX016-7 and HX016-9: These two preclinical bispecific antibodies target dual specificities of PD-L1xVEGF and PD-1xVEGF, respectively. Their innovative design aims to thwart both tumor immune evasion and facilitate new blood vessel formation (angiogenesis). This dual-target approach is expected to introduce a novel treatment landscape for solid tumors and enhance efficacy against complex malignancies.

4. HX301 (Narazaciclib): Co-developed with Traws Pharma, this CSF-1R inhibitor is currently in Phase II trials focused on glioblastoma. HX301 is undergoing evaluations in combination with temozolomide (TMZ), aiming to improve anti-tumor effectiveness and potentially change the treatment paradigm for one of the most aggressive brain cancers.

A Vision for the Future

Dr. Henry Li, CEO and Chief Scientific Officer of HanxBio, presented the posters and underscored the importance of their innovations, stating, "Our AACR presentations reflect HanxBio's commitment to redefining cancer and autoimmune disease treatment through cutting-edge bispecific antibody platforms. With HX044 advancing in clinical trials and a robust preclinical pipeline, we are poised to deliver transformative therapies that address critical unmet needs for patients globally." He elaborated on their strategy that focuses on targeting multiple pathways simultaneously and exploring coordinated binding (cis-binding) to enhance safety and activity, thereby improving outcomes for patients battling difficult-to-treat cancers.

About Hanx Biopharmaceuticals, Ltd.

HanxBio, driven by a strong commitment to innovation, specializes in discovering and developing first-in-class (FIC) and best-in-class (BIC) therapies targeting cancer and autoimmune diseases. Their expertise spans structural biology, translational medicine, and precision clinical development, strategically positioning them to offer safe and effective treatments to address global health challenges.

As the biotech landscape continues to evolve, Hanx Biopharmaceuticals is actively shaping the future of cancer treatment, promising hope and improved outcomes for patients worldwide.

For more information regarding their groundbreaking work, media inquiries can be directed to [email protected]